Yatharth Hospital and Trauma Care Services Limited (YATHARTH) AI Stock Analysis

• Market Cap: ₹75.22B
• Dividend Yield: N/A
• Average Volume (3M): 42.59K
• Price to Earnings (P/E): 51.5
• Beta (1Y): 0.97
• Revenue Growth: 27.33%
• EPS Growth: -1.67%
• Country: IN
• Employees: 3,607
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 4.40
• Shares Outstanding: 96,354,355
• 10 Day Avg. Volume: 33,267
• 30 Day Avg. Volume: 42,593
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹661.00
• Price Target Upside: -15.33% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 69 Neutral
• Price Target: ₹661.00 ▼(-15.33% Downside)

Yatharth Hospital's stock score reflects strong financial performance, including revenue growth and improved profitability. Bullish technical indicators are offset by high valuation levels, and despite a strong balance sheet, negative cash flow due to capital expenditures remains a concern. Overbought technical signals suggest potential for a price correction.

Yatharth Hospital and Trauma Care Services Limited Business Overview & Revenue Model

Company Description

Yatharth Hospital & Trauma Care Services Limited owns and operates super-specialty hospitals in Delhi and Madhya Pradesh. The company offers services in the areas of gynecology; gastroenterology; pulmonology; pediatric; nephrology and urology; cardiology; orthopedics and spine and rheumatology; neurosciences; medicine; general surgery; ENT; physiotherapy and rehabilitation; interventional spine and pain medicine; nutrition and health; pathology and laboratory medicine; dentistry; ophthalmology; dermatology; anesthesiology; radiology; and psychology and psychiatry. The company was incorporated in 2008 and is based in Noida, India.

How the Company Makes Money

Yatharth Hospital and Trauma Care Services Limited generates revenue primarily through the provision of healthcare services. The company's key revenue streams include patient fees for inpatient and outpatient services, surgical procedures, and specialized medical treatments. Additionally, revenue is derived from diagnostic services, laboratory tests, and pharmacy sales within the hospital premises. YATHARTH may also engage in partnerships with insurance companies, facilitating patient access to medical services covered under insurance plans, which contributes to its earnings. The hospital's commitment to maintaining modern medical facilities and employing skilled healthcare professionals further supports its revenue generation.

Yatharth Hospital and Trauma Care Services Limited Financial Statement Overview

Summary

Yatharth Hospital shows strong revenue growth and improved profitability with a high gross profit margin. The balance sheet reflects a stronger equity base and reduced leverage, though high asset growth could indicate potential over-leverage. Cash flow has improved but remains negative due to capital expenditures, necessitating careful investment management.

Income Statement

Yatharth Hospital has demonstrated strong revenue growth, with a significant increase from 2020 to 2025. The gross profit margin is consistently high, indicating efficiency in cost management. Net profit margin has improved, showcasing enhanced profitability. However, the slight drop in EBIT margin over the years suggests room for operational efficiency improvements.

Balance Sheet

The company's debt-to-equity ratio has improved significantly, reflecting a stronger equity base and reduced leverage. The substantial increase in stockholders' equity indicates robust growth in assets relative to liabilities. However, the high increase in total assets compared to liabilities suggests potential over-leverage if not managed properly.

Cash Flow

Operating cash flow has improved from negative to positive, signifying better cash management. However, free cash flow remains negative due to high capital expenditures, indicating ongoing investments in growth. The operating cash flow to net income ratio has improved, but sustaining this trend is crucial for long-term financial health.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.27B	8.80B	6.71B	5.20B	4.01B	2.29B
Gross Profit	6.11B	5.39B	5.37B	4.27B	3.20B	1.82B
EBITDA	2.26B	2.36B	1.96B	1.37B	1.13B	675.27M
Net Income	1.30B	1.31B	1.14B	657.68M	441.62M	181.60M
Balance Sheet
Total Assets	0.00	17.31B	10.19B	4.86B	4.26B	3.09B
Cash, Cash Equivalents and Short-Term Investments	2.44B	5.15B	2.39B	382.36M	120.31M	51.52M
Total Debt	0.00	115.86M	846.47M	2.67B	2.64B	1.93B
Total Liabilities	-9.32B	940.45M	1.45B	3.03B	3.09B	2.28B
Stockholders Equity	9.32B	16.05B	8.74B	1.83B	1.17B	724.55M
Cash Flow
Free Cash Flow	0.00	-1.61B	-964.43M	439.70M	468.01M	235.38M
Operating Cash Flow	0.00	1.50B	-30.78M	637.84M	599.35M	436.73M
Investing Cash Flow	0.00	-4.20B	-2.26B	-203.10M	-521.75M	-212.38M
Financing Cash Flow	0.00	5.19B	3.04B	-177.48M	-11.24M	-190.50M

Yatharth Hospital and Trauma Care Services Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 780.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:YATHARTH, the sentiment is Positive. The current price of 780.65 is above the 20-day moving average (MA) of 775.04, above the 50-day MA of 715.46, and above the 200-day MA of 546.36, indicating a bullish trend. The MACD of 20.50 indicates Positive momentum. The RSI at 58.86 is Neutral, neither overbought nor oversold. The STOCH value of 29.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:YATHARTH.

Yatharth Hospital and Trauma Care Services Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASTERDM	77 Outperform	323.85B	98.55	156.88%	0.80%	-53.19%	-94.01%
KIMS	71 Outperform	290.78B	77.23	17.99%	―	24.71%	19.17%
YATHARTH	69 Neutral	₹75.22B	51.52	―	―	27.33%	-1.67%
HCG	61 Neutral	90.85B	242.22	4.81%	―	16.85%	-29.57%
INDRAMEDCO	61 Neutral	40.85B	24.36	26.98%	1.01%	6.80%	21.31%
SHALBY	58 Neutral	26.70B	-5,226.22	0.63%	0.49%	13.03%	-100.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Yatharth Hospital and Trauma Care Services Limited Corporate Events

Yatharth Hospital Appoints New Statutory Auditors

Yatharth Hospital & Trauma Care Services Limited has announced a change in its statutory auditors, appointing M/s. MSKA & Associates, a member firm of BDO International, as the new auditors for the company and its material subsidiary, AKS Medical & Research Centre Private Limited. This change follows the resignation of the previous auditors and is subject to approval at the upcoming Annual General Meeting. The appointment is expected to enhance the company’s audit and assurance capabilities, potentially impacting its financial reporting and compliance processes.

Yatharth Hospital Announces Key Appointments and Financial Results

Yatharth Hospital and Trauma Care Services Limited announced key decisions from its board meeting, including the approval of un-audited financial results for the first quarter of 2025 and the appointment of M/s MKP & Associates as Secretarial Auditor for a five-year term. The company also re-appointed M/s Subodh Kumar & Co. as Cost Auditor for the financial year 2025-26 and appointed M/s Saurav Upadhyay & Associates as Scrutinizer for its upcoming Annual General Meeting. These appointments and financial disclosures are expected to enhance the company’s governance and operational transparency, potentially strengthening its position in the healthcare sector.

Yatharth Hospital Announces Auditor Resignation

Yatharth Hospital & Trauma Care Services Limited announced a change in its auditors, with M/s. R Nagpal Associates resigning as the statutory auditor of the company and M/s. MAPPS & Company resigning as the auditor of its material subsidiary, AKS Medical & Research Centre Private Limited. The resignations were due to disagreements over the proposed remuneration, which the auditors felt was not commensurate with the efforts required to conduct a thorough audit. This change may impact the company’s financial reporting and auditing processes, potentially affecting stakeholders’ confidence.